| Company Name: |
SPIRO PHARMA |
| Tel: |
|
| Email: |
eric_feng1954@126.com |
5-((7-(Benzyloxy)quinazolin-4-yl)amino)-4-fluoro-2-methylphenol manufacturers
- ZM323881
-
- $1980.00
-
2026-07-27
- CAS:193001-14-8
- Purity:
- Supply Ability: 10g
|
| | 5-((7-(Benzyloxy)quinazolin-4-yl)amino)-4-fluoro-2-methylphenol Basic information |
| Product Name: | 5-((7-(Benzyloxy)quinazolin-4-yl)amino)-4-fluoro-2-methylphenol | | Synonyms: | KDR/FLK-1 INHIBITOR V;VEGF RECEPTOR 2 KINASE INHIBITOR V;ZM323881;4-Fluoro-2-methyl-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]phenol;CS-744;Phenol, 4-fluoro-2-methyl-5-[[7-(phenylmethoxy)-4-quinazolinyl]amino]-;5-((7-(Benzyloxy)quinazolin-4-yl)amino)-4-fluoro-2-methylphenol | | CAS: | 193001-14-8 | | MF: | C22H18FN3O2 | | MW: | 375.4 | | EINECS: | | | Product Categories: | | | Mol File: | Mol File |  |
| | 5-((7-(Benzyloxy)quinazolin-4-yl)amino)-4-fluoro-2-methylphenol Chemical Properties |
| Boiling point | 543.6±50.0 °C(Predicted) | | density | 1.342±0.06 g/cm3(Predicted) | | storage temp. | Store at -20°C | | solubility | Soluble in DMSO | | form | White to off-white solid. | | pka | 9.99±0.23(Predicted) |
| | 5-((7-(Benzyloxy)quinazolin-4-yl)amino)-4-fluoro-2-methylphenol Usage And Synthesis |
| Definition | ChEBI: ZM 323881 is a member of the class of quinazolines carrying 2-fluoro-4-methyl-5-hydroxyanilino and benzyloxy substituents at positions 4 and 7 respectively. It has a role as a vascular endothelial growth factor receptor antagonist. It is a benzyl ether, an aromatic ether, a member of quinazolines, a secondary amino compound, a substituted aniline, a halophenol, a member of monofluorobenzenes, an organic cation and a fluorophenol. It is a conjugate base of a ZM 323881(1+). | | Biological Activity | zm323881 inhibits vegf-a-induced endothelial cell proliferation (ic50 = 8 nm) and vegf-r2 tyrosine phosphorylation (ic50 < 2 nm).vascular endothelial growth factor (vegf) increases vascular permeability and angiogenesis in many pathological conditions, such as cancer, arthritis, and diabetes. vegf activates vegf-receptor 1 (vegf-r1) and vegf-receptor 2 (vegf-r2) that autophosphorylate to initiate a signaling cascade resulting in angiogenesis and increased microvascular permeability. zm323881 is a potent and selective inhibitor of vegf-r2 tyrosine kinase. | | in vitro | zm323881 was found to inhibit vegf-a-induced endothelial cell proliferation (ic50 = 8 nm) and vegf-r2 tyrosine phosphorylation in vitro (ic50 < 2 nm) [1]. | | in vivo | vegf-amediated increases in vascular permeability in perfused mesenteric microvessels in vivo were reversibly abolished by both zm323881 and the class iii receptor tyrosine kinase inhibitor ptk787/zk222584, suggesting that vegf-r2 phosphorylation is necessary for vegf-a-mediated increases in microvascular permeability in vivo [1]. | | target | VEGFR-2/KDR | | references | [1] whittles ce, pocock tm, wedge sr, kendrew j, hennequin lf, harper sj, bates do. zm323881, a novel inhibitor of vascular endothelial growth factor-receptor-2 tyrosine kinase activity. microcirculation. 2002;9(6):513-22. |
| | 5-((7-(Benzyloxy)quinazolin-4-yl)amino)-4-fluoro-2-methylphenol Preparation Products And Raw materials |
|